- Home
- Companies
- united kingdom
- t standard polystyrene disposable cell
Show results for
Refine by
T Standard Polystyrene Disposable Cell Suppliers Serving United Kingdom
38 companies found
based inSan Diego, CALIFORNIA (USA)
Invivoscribe is a global leader in molecular diagnostics, providing a comprehensive range of standardized, CE-marked in vitro diagnostic products and companion diagnostics for hematology-oncology. The company's offerings include research use only ...
based inOxford, UNITED KINGDOM
Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford ...
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
ImmunoBody vaccines are designed to generate potent T cell responses capable of a broad anti-tumour effect. They are DNA vaccines that encode a protein in the form of an antibody, but the parts of the antibody that would normally bind to the target ...
based inCambridge, MASSACHUSETTS (USA)
The human body is an ecosystem. Trillions of microbes call us home. They form the human microbiome, which performs critical functions that preserve our health including modulating our immune system and providing colonization resistance against ...
From Ruslan Medzhitov's discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman's efforts to identify and clone CD4 and CD8, molecules on the ...
based inDallas, TEXAS (USA)
Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C and GT production and ...
based inPiscataway, NEW JERSEY (USA)
Genscript is the world’s leading biotech company providing life sciences services and products. With gene synthesis, peptide, protein, antibody and preclinical drug development service capabilities, we are internationally recognized as a leading ...
based inBoston, MASSACHUSETTS (USA)
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inWien, AUSTRIA
BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and ...
The high level of interferon induced by the delNS vector activates immunological defence reactions against cancer. It also stimulates the production of antiviral ...
based inBielefeld, GERMANY
PlasmidFactory GmbH & Co. KG is a globally active biopharmaceutical company, founded in Bielefeld, Germany, in 2000. The leading contract manufacturing organization (CMO) for plasmid and minicircle DNA has a strong customer base in the fields of ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
The Celluris’ novel solution, named RfuCAR, was engineering in order to respond some challenges addressed by clinical trials around the world. RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
Our therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach. GDT cells are a component of the lymphocytes (white blood cells) present within ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid ...
based inSan Francisco, CALIFORNIA (USA)
We were founded with the mission of creating a world without infectious disease. We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. ...
We are exploiting the unique immunology of human cytomegalovirus, or HCMV, a commonly occurring virus in humans, as a delivery vehicle – or vector – for vaccines to potentially treat and prevent infection by pathogens that are refractory ...
based inShirley, NEW YORK (USA)
Creative Biogene provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. Creative Biogene holds a leadership position in the global market and is committed to improving the human ...
CRISPR/Cas9 technology has been used as a genome-editing tool for multiple cell lines, such as tumor cell line and embryonic stem cell lines. Primary T cell, as an important class of immune cells system, play an extremely important role in immunity ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody ...
based inSeattle, WASHINGTON (USA)
AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged ...
The American Lung Association describes acute respiratory distress syndrome (ARDS) as a life-threatening lung injury that allows fluid to leak into the lungs. Breathing becomes difficult and oxygen cannot get into the body. Most people who get ARDS ...
based inDuisburg, GERMANY
Genekam Biotechnology AG was found in 1999. It started offering DNA-Tests in 2001. From 2004, it started development of PCR kits while exporting to 5 countries, today (2015) it exports to 70 countries in the world. Genekam covers different targets ...
There are many laboratories developing CAR T-cell therapies. Genekam has a number of kits to develop CAR T-Cell therapy e.g. isolate large number of T cells (CD4 / CD8) from blood or other source. This isolation kit will generate larger number of ...
based inCharlottesville, VIRGINIA (USA)
LumaCyte is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This revolutionary ...